483
Jiangsu Anbison Pharmaceutical Co., Ltd.Jiangsu Anbison Pharmaceutical Co., Ltd. – FDA 483, Aug 14, 2023
Record Details
An FDA inspection of Anbison Pharmaceutical Co., Ltd. in Taizhou, China, revealed a significant issue with equipment design and qualification. The firm's equipment qualifications for a critical manufacturing process lacked sufficient robustness tests, failing to ensure consistency and potentially impacting finished drug product quality. This indicates a concern regarding the firm's control over its manufacturing processes.
View Company Profile
ID · 1f011bf3-2306-4f24-b98b-4d3da465772e
Other documents for Jiangsu Anbison Pharmaceutical Co., Ltd.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.